A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Conditions:   Chronic Kidney Diseases;   Pruritus Interventions:   Drug: CR845 0.25 mg Oral Tablet;   Drug: CR845 0.5 mg Oral Tablet;   Drug: CR845 1 mg Oral Tablet;   Drug: Placebo Oral Tablet Sponsor:   Cara Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials